의료용 AI 가상 동반자 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI virtual companions in healthcare market size is expected to grow from USD 3.29 billion in 2025 to USD 4.34 billion in 2026 and is forecast to reach USD 17.82 billion by 2031 at 32.66% CAGR over 2026-2031.

This report is Segmented by Component (Software, Services), Deployment Mode (Cloud-Based, On-Premises), Companion Type (Chatbot-Based, Voice-Enabled, Multimodal), Application (Mental Health, Chronic Disease, Elder Care, Medication Adherence), End User (Hospitals, Home Care, Assisted Living, Payers, Consumers), and Geography (North America, Europe, Asia-Pacific, MEA, South America).

Global AI Virtual Companions In Healthcare Market Trends and Insights

Expanded Access to Personalized Patient Support

The AI virtual companions in the healthcare market is gaining from a long-standing gap between what patients need between visits and what clinical teams can realistically provide at scale. Traditional care models still concentrate meaningful interaction around appointments, which leaves many patients without structured support during preparation, recovery, and routine follow-up. That gap has become easier to address because conversational systems can deliver timely and context-aware guidance before and after treatment, often without adding direct pressure on physician schedules. A 2026 study at Mount Sinai Health System validated a voice-based assistant for pre-procedural preparation and showed that intervention failure rates fell from 6.0% in the initial phase to 2.6% after optimization, which suggests these tools can improve operational performance in real care settings. The same use case also gives providers richer intake data before the clinician encounter, which can shorten visit preparation time and improve context for decision-making. As health systems place more weight on workflow efficiency and patient readiness, the AI virtual companions in healthcare market is moving from basic chat support toward more structured care pathway support.

Rising Demand for Medication Adherence and Chronic Disease Management

The AI virtual companions in healthcare market is also being supported by the steady need for better medication adherence and day-to-day disease management outside the clinic. Chronic conditions often require repeated behavioral reinforcement rather than one-time education, and that makes conversational support useful because it can be repeated without a similar rise in delivery cost. A 2025 randomized clinical trialin npj Digital Medicine found that a digital medication system with audio reminders, real-time dose recording, and caregiver app connectivity improved adherence outcomes compared with controls over a 12-month period in patients with severe mental disorders. A 2026 scoping review in Digital Health also found measurable improvements across chatbot use cases in diabetes, hypertension, asthma, and cancer support, which strengthens the case for conversational tools in routine self-management. These findings matter because they support the idea that adherence support can become a scalable service layer rather than a labor-heavy outreach function. As care organizations look for low-friction ways to manage large patient panels, the AI virtual companions in healthcare market is finding a durable role in chronic disease support programs.

Clinical Trust Gaps in Generative AI Responses

Clinical trust remains a core restraint because health systems do not judge these tools only by user engagement or language quality. They also judge them by whether responses can remain safe, stable, and clinically appropriate in sensitive situations such as medication guidance and mental health support. The AI virtual companions in healthcare market still faces caution because large language models can produce answers that sound credible even when they contain serious errors. The FDA advisory discussion in November 2025 highlighted hallucinations, context failures, demographic disparities, and model drift as risks that require adverse event reporting and clearer consent standards. A 2026 analysis hosted by the National Library of Medicine also concluded that existing regulatory approaches do not fully balance broad access against the range of clinical risks, and it recommended a hybrid model with ongoing monitoring and independent auditing . This has a direct commercial effect because providers and payers now place greater weight on published validation, auditability, and post-market oversight before they commit to scaled deployment.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Adoption of AI-Based Behavioral Health Solutions
2. Aging Population Requiring Continuous Low-Touch Care
3. Reimbursement Uncertainty for Conversational AI

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The software segment held 62.2% of the AI virtual companions in healthcare market in 2025, and it was forecast to grow at a 33.8% CAGR through 2031. That position reflects how software platforms can scale across multiple health system workflows without the manufacturing, maintenance, and deployment burdens attached to device-heavy models. Once a platform is embedded in triage, pre-visit intake, follow-up messaging, and support navigation, the vendor can expand account value through additional use cases rather than through separate product categories. This creates a reinforcing cycle where more usage produces more interaction data, and more interaction data can improve model performance, workflow tuning, and product credibility. The result is that established software vendors often gain quality and procurement advantages over smaller entrants that do not yet have similar dataset depth or deployment history.

The services side remains smaller, but it still plays an important role because enterprise implementation rarely ends with software access alone. Health systems often need integration support, workflow customization, governance design, privacy review, training, and ongoing model maintenance before they can use these tools widely. A 2026 study in Frontiers in Artificial Intelligenceshowed that fully offline language models combined with virtual physician avatars could support privacy-preserving clinical interactions without cloud connectivity, which expands the software opportunity into bandwidth-constrained and data-residency-sensitive settings. That finding matters because it suggests the software layer can move into environments that were once seen as difficult for cloud-dependent conversational tools. The AI virtual companions in healthcare industry is therefore seeing software retain leadership not only because it is lighter to distribute, but also because new deployment architectures are widening its usable footprint. Over time, services revenue should remain attached to software growth because deeper adoption usually means deeper integration effort. The AI virtual companions in healthcare market should continue to favor vendors that can combine product scale with implementation discipline and privacy-ready deployment models.

Chatbot-based solutions held 54.3% of the companion type segment in 2025, which shows the staying power of text-led interfaces in healthcare communication. Text chat remains the easiest format to place into patient portals, secure messaging tools, and mobile care pathways, and it can be deployed with little change to existing user behavior. It also allows vendors to scale basic support functions quickly across triage, education, navigation, and follow-up use cases. That first-mover advantage explains why chatbot formats still lead current revenue even as richer interaction models attract more clinical attention. For many providers, a text-based starting point remains the lowest-friction path into the AI virtual companions in healthcare market.

The faster expansion is expected in multimodal avatars, which were forecast to grow at a 34.1% CAGR through 2031. This reflects the view that voice, visual presence, and emotionally legible interaction may improve comprehension and comfort in ways that pure text cannot always match. A June 2026 ChristianaCare study found that cancer patients who viewed AI physician avatar videos before radiation visits reported lower anxiety, stronger understanding of their treatment plan, and higher satisfaction than those who watched standard educational videos. A 2025 Frontiers in Public Health study also reported that avatar customization improved user intention to engage with virtual health systems by strengthening social presence. Voice-enabled systems continue to hold strategic value as well because they reduce interface barriers for older adults and for users who do not engage comfortably with touch-heavy applications. The AI virtual companions in healthcare market is therefore not shifting away from chat, but it is moving toward richer formats where clinical experience and engagement outcomes can be measured more directly. Vendors that prove outcome gains from multimodal delivery may win higher-value contracts even if text remains the broader installed base.

Complete Report Scope:

• By Component
  • Software
  • Hardware
  • Services
• By Application
  • In Vivo Diagnostics
  • In Vitro Diagnostics
• By Deployment Mode
  • Cloud Based
  • Hybrid
  • On Premises
• By Companion Type
  • Chatbot-Based
  • Voice-Enabled
  • Multimodal
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Diagnostic Laboratories
  • Clinics and Other Healthcare Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.1% of AI virtual companions in healthcare market share in 2025, which made it the largest regional market by current revenue. The region benefits from established digital health infrastructure, wider interoperability adoption, and stronger enterprise readiness for AI workflow integration than many other regions. Buyers in the United States increasingly expect these tools to connect with existing care systems rather than operate as isolated chat interfaces. That expectation favors vendors that can support documentation, pre-visit screening, summarization, and patient engagement within broader clinical workflows. Microsoft strengthened this enterprise-facing direction in June 2026 when it announced a collaboration with Mayo Clinic to build a frontier healthcare AI model that combines Mayo's de-identified longitudinal clinical data with Microsoft's AI and cloud engineering capabilities. Microsoft also launched Copilot Health in preview in May 2026 for U.S. Microsoft 365 subscribers, which signaled growing effort to normalize AI-supported health record interpretation and health query support in a HIPAA-compliant environment.

Asia Pacific was forecast to grow at a 34.5% CAGR through 2031, which made it the fastest-growing geography in the AI virtual companions in healthcare market. Growth in this region is being pulled by aging population pressure, labor shortages in caregiving, and public interest in scalable support tools that can remain active in homes and community settings. South Korea has become one of the clearest examples because it entered super-aged society status by the end of 2025, and public distribution of AI companion robots has already moved beyond concept discussion. The South Jeolla Province outcome data showing a 63% drop in geriatric depression scores adds practical evidence that these tools can contribute to measurable well-being outcomes in elderly populations. Japan and China also add scale to the regional opportunity because aging and healthcare access pressure there support demand for assistive and low-touch care models. India and Australia contribute through different routes, with India offering a large digitally connected user base and Australia showing stronger institutional digital health purchasing capacity.

Europe remains a maturing regional market where policy structure and reimbursement pathways carry more weight than pure novelty demand. EU digital health frameworks and country-level reimbursement routes give vendors a clearer route to formal market participation than in some earlier-stage regions. Germany's DiGA pathway is especially relevant because it offers a structured route for reimbursable digital health applications, and that gives AI companion vendors a concrete market entry target. The United Kingdom also remains open to clinical AI deployment through NHS-linked partnerships and digital service pilots, which keeps the region commercially relevant even when adoption moves at a measured pace. Middle East and Africa is still earlier in development, but GCC investment in digital health transformation aligns well with mental health support and chronic disease management use cases. South America remains a smaller base today, yet large urban populations, growing digital health use, and underserved rural care needs support long-run room for expansion across the AI virtual companions in healthcare market.

1. Alphabet Inc. (Google Health / DeepMind)
2. Microsoft
3. NVIDIA
4. Siemens Healthineers
5. GE HealthCare Technologies Inc.
6. Koninklijke Philips
7. Roche
8. Tempus AI, Inc.
9. Aidoc Medical Ltd.
10. Qure.AI Technologies Private Limited
11. Heartflow
12. PathAI, Inc.
13. Paige.AI, Inc.
14. Ada Health GmbH
15. AliveCor
16. Butterfly Network, Inc.
17. Digital Diagnostics
18. Lunit
19. Ibex Medical Analytics Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for Faster Triage and Early Disease Detection
  • 4.2.2 Expansion of AI-Enabled Radiology and Pathology Workflows
  • 4.2.3 Multi-Modal Clinical Data Convergence Improves Diagnostic Confidence
  • 4.2.4 Provider Push Toward Workflow Automation in Overburdened Health Systems
  • 4.2.5 Integration With Wearables and Remote Monitoring Expands Diagnostic Reach
  • 4.2.6 Growing Investment in Clinical Validation and Interoperable AI Platforms
• 4.3 Market Restraints
  • 4.3.1 Algorithm Explainability and Liability Concerns Slow Clinical Trust
  • 4.3.2 High Integration Cost Across PACS, EHR, and Hospital IT Stacks
  • 4.3.3 Data Privacy, Sovereignty, and Cross-Border Model Training Constraints
  • 4.3.4 Regulatory Heterogeneity and Revalidation Burden for Model Updates
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts (Value; volume for key analytes)

• 5.1 By Component
  • 5.1.1 Software
  • 5.1.2 Hardware
  • 5.1.3 Services
• 5.2 By Application
  • 5.2.1 In Vivo Diagnostics
  • 5.2.2 In Vitro Diagnostics
• 5.3 By Deployment Mode
  • 5.3.1 Cloud Based
  • 5.3.2 Hybrid
  • 5.3.3 On Premises
• 5.4 By Companion Type
  • 5.4.1 Chatbot-Based
  • 5.4.2 Voice-Enabled
  • 5.4.3 Multimodal
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Diagnostic Imaging Centers
  • 5.5.3 Diagnostic Laboratories
  • 5.5.4 Clinics and Other Healthcare Providers
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Alphabet Inc. (Google Health / DeepMind)
  • 6.3.2 Microsoft Corporation
  • 6.3.3 NVIDIA Corporation
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Koninklijke Philips N.V.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 Tempus AI, Inc.
  • 6.3.9 Aidoc Medical Ltd.
  • 6.3.10 Qure.ai Technologies Private Limited
  • 6.3.11 Heartflow, Inc.
  • 6.3.12 PathAI, Inc.
  • 6.3.13 Paige.AI, Inc.
  • 6.3.14 Ada Health GmbH
  • 6.3.15 AliveCor, Inc.
  • 6.3.16 Butterfly Network, Inc.
  • 6.3.17 Digital Diagnostics, Inc.
  • 6.3.18 Lunit Inc.
  • 6.3.19 Ibex Medical Analytics Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment